Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bonoste is an oral potassium supplement developed and marketed by Nucitec in Mexico. It is formulated as dispersible or effervescent tablets containing potassium bicarbonate, potassium bitartrate, and citric acid. Bonoste is indicated for the treatment and prevention of hypokalemia (potassium deficiency) of various etiologies, and as an adjuvant therapy in patients receiving diuretics, corticosteroids, or carbonic anhydrase inhibitors, which can deplete potassium levels. Note that another unrelated product named Bonoste (containing ibandronic acid) is marketed by Gedeon Richter in Germany for osteoporosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on potassium bicarbonate + potassium bitartrate + citric acid.